Christian Adolf1, Anton Köhler2, Anna Franke1, Katharina Lang3,4, Anna Riester1, Anja Löw2, Daniel A Heinrich1, Martin Bidlingmaier1, Marcus Treitl5, Roland Ladurner6, Felix Beuschlein1,7, Wiebke Arlt3,4, Martin Reincke1. 1. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany. 2. Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Munich, Germany. 3. Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom. 4. Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom. 5. Klinik und Poliklinik für Radiologie, Klinikum der Universität München, LMU München, Munich, Germany. 6. Klinik für Viszeral- und Endokrine Chirurgie, Klinikum der Universität München, LMU München, Munich, Germany. 7. Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland.
Abstract
Context: Primary aldosteronism (PA) represents the most frequent form of endocrine hypertension. Hyperaldosteronism and hypercortisolism both induce excessive left ventricular hypertrophy (LVH) compared with matched essential hypertensives. In recent studies frequent cosecretion of cortisol and aldosterone has been reported in patients with PA. Objective: Our aim was to investigate the impact of cortisol cosecretion on LVH in patients with PA. We determined 24-hour excretion of mineralocorticoids and glucocorticoids by gas chromatography-mass spectrometry and assessed cardiac remodeling using echocardiography initially and 1 year after initiation of treatment of PA. Patients: We included 73 patients from the Munich center of the German Conn's registry: 45 with unilateral aldosterone-producing adenoma and 28 with bilateral adrenal hyperplasia. Results: At the time of diagnosis, 85% of patients with PA showed LVH according to left ventricular mass index [(LVMI); median 62.4 g/m2.7]. LVMI correlated positively with total glucocorticoid excretion (r2 = 0.076, P = 0.018) as well as with tetrahydroaldosterone excretion (r2 = 0.070, P = 0.024). Adrenalectomy led to significantly reduced LVMI in aldosterone-producing adenoma (P < 0.001) whereas mineralocorticoid receptor antagonist therapy in bilateral adrenal patients with hyperplasia reduced LVMI to a lesser degree (P = 0.024). In multivariate analysis, the decrease in LVMI was positively correlated with total glucocorticoid excretion and systolic 24-hour blood pressure, but not with tetrahydroaldosterone excretion. Conclusion: Cortisol excess appears to have an additional impact on cardiac remodeling in patients with PA. Treatment of PA by either adrenalectomy or mineralocorticoid receptor antagonist improves LVMI. This effect was most pronounced in patients with high total glucocorticoid excretion.
Context: Primary aldosteronism (PA) represents the most frequent form of endocrine hypertension. Hyperaldosteronism and hypercortisolism both induce excessive left ventricular hypertrophy (LVH) compared with matched essential hypertensives. In recent studies frequent cosecretion of cortisol and aldosterone has been reported in patients with PA. Objective: Our aim was to investigate the impact of cortisol cosecretion on LVH in patients with PA. We determined 24-hour excretion of mineralocorticoids and glucocorticoids by gas chromatography-mass spectrometry and assessed cardiac remodeling using echocardiography initially and 1 year after initiation of treatment of PA. Patients: We included 73 patients from the Munich center of the German Conn's registry: 45 with unilateral aldosterone-producing adenoma and 28 with bilateral adrenal hyperplasia. Results: At the time of diagnosis, 85% of patients with PA showed LVH according to left ventricular mass index [(LVMI); median 62.4 g/m2.7]. LVMI correlated positively with total glucocorticoid excretion (r2 = 0.076, P = 0.018) as well as with tetrahydroaldosterone excretion (r2 = 0.070, P = 0.024). Adrenalectomy led to significantly reduced LVMI in aldosterone-producing adenoma (P < 0.001) whereas mineralocorticoid receptor antagonist therapy in bilateral adrenal patients with hyperplasia reduced LVMI to a lesser degree (P = 0.024). In multivariate analysis, the decrease in LVMI was positively correlated with total glucocorticoid excretion and systolic 24-hour blood pressure, but not with tetrahydroaldosterone excretion. Conclusion:Cortisol excess appears to have an additional impact on cardiac remodeling in patients with PA. Treatment of PA by either adrenalectomy or mineralocorticoid receptor antagonist improves LVMI. This effect was most pronounced in patients with high total glucocorticoid excretion.
Authors: Troy H Puar; Chin Kai Cheong; Roger S Y Foo; Seyed Ehsan Saffari; Tian Ming Tu; Min Ru Chee; Meifen Zhang; Keng Sin Ng; Kang Min Wong; Andrew Wong; Foo Cheong Ng; Tar Choon Aw; Joan Khoo; Linsey Gani; Thomas King; Wann Jia Loh; Shui Boon Soh; Vanessa Au; Tunn Lin Tay; Eberta Tan; Lily Mae; Jielin Yew; Yen Kheng Tan; Khim Leng Tong; Sheldon Lee; Siang Chew Chai Journal: Front Endocrinol (Lausanne) Date: 2022-06-30 Impact factor: 6.055
Authors: Karl-Heinz Storbeck; Lina Schiffer; Elizabeth S Baranowski; Vasileios Chortis; Alessandro Prete; Lise Barnard; Lorna C Gilligan; Angela E Taylor; Jan Idkowiak; Wiebke Arlt; Cedric H L Shackleton Journal: Endocr Rev Date: 2019-12-01 Impact factor: 19.871
Authors: Christian Adolf; Leah T Braun; Carmina T Fuss; Stefanie Hahner; Heike Künzel; Laura Handgriff; Lisa Sturm; Daniel A Heinrich; Holger Schneider; Martin Bidlingmaier; Martin Reincke Journal: Endocrine Date: 2020-06-27 Impact factor: 3.633